Despite global progress, HIV remains one of the world’s most tenacious public health challenges and much more needs to be done to ensure that people everywhere have access to care.
Johnson & Johnson introduced nine HIV medicines and continues working to investigate the potential of our portfolio of treatments to address the needs of people living with HIV, including an ultra-long-acting injectable drug that would make treatment easier for patients. Beyond research and development (R&D), we continue to explore the best approaches to support access to our medicines for people living with HIV around the world.